Login to Your Account

Clinic Roundup

Monday, July 29, 2013
• Cerespir Inc., of New York, disclosed positive interim clinical results from the Phase II trial by Chiesi Farmaceutici SpA, of Parma, Italy, testing CHF 5074, a first-in-class small-molecule microglia modulator, in patients with mild cognitive impairment (MCI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription